In Brief: Merck's Fosamax
Merck's Fosamax: FDA's Endocrine & Metabolic Drugs Advisory Committee is scheduled to review Fosamax (alendronate, NDA 20-560) for osteoporosis July 13. The company disclosed June 5 that a three-year, 994-patient Phase III study to be presented at the Endocrine Society annual meeting June 14 found a 48% reduction in new vertebral fractures compared to placebo. The drug was licensed to Merck by Istituto Gentili of Pisa, Italy. The meeting will begin at 8 a.m. at the Holiday Inn in Silver Spring, Md...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth